The new version of the basic medicine adjustment starts the "double envelope" mode!

For enterprises, the introduction of basic medicines has advantages in basic medicines, but basic medicines are not a panacea
.
Don’t you see how many of the so-called gold varieties that entered the basic medicines that year have not really released the volume for so many years.
The company still needs a clear product planning and positioning, based on their own knowledge, which market segment they are positioned in, and your resources What is the gap or problem with the positioning target? The most important thing is how to study and judge the market prospects of the basic drugs and whether there is a set of product promotion strategies for the basic drugs
.
At the same time, we must also consider whether the basic drug has the corresponding competitive resources in its treatment field? ! If there is nothing, it is simply a pit and want to enter the basic medicine catalog, but it is not very meaningful
.
After entering the basic medicine, the first challenge is the test of mass procurement
.
500 varieties are blocking the way, and it is undoubtedly a policy trend to cut prices of basic medicines in 2021
.
It is estimated that when many varieties have not yet seen the consistency evaluation and DRG, they have already fallen in front of the door of at least a 50% reduction in the purchase price of the quantity
.

Accompanied by 2022 with volume purchases
.
This kind of price-cutting weapon basically uses the over-evaluated varieties and basic medicines with a large amount of exclusive use.
Has the company been fully ideologically prepared to deal with it? ! Although he has the identity of a basic medicine, if the strategy is not well thought out, he still wants to use the old idea of ​​"opening academic conferences is to let'experts replace salt'" for market promotion.
It is estimated that the road ahead is still bumpy
.

Although the basic medicine management adjustment measures have been solicited for external opinions, it is still a big question mark that basic medicines can be fully implemented as scheduled in 2022
.
The full expansion of the basic medicine is already a no-brainer
.
Fundamental medicine is a policy product, which has all the benefits brought by the catalogue and the risks brought by the policy
.
I won't go into details here
.
Now that the basic medicine is here, let us wait for the flowers to bloom together
.
For companies, what they need to do now is not to put forward any comments on this draft for soliciting comments.
The general direction has been set.
The points for the extra points are added.
As for whether to enter the catalog, it is naturally a matter of course
.